Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

VIENNA, Sept. 30 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes at the Annual Conference of the European Association for the Study of Diabetes in Vienna, Austria. Results of the study demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period. Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

"The results from the ITCA 650 phase 1b study demonstrate the potential for DUROS continuous delivery of exenatide to improve the treatment of type 2 diabetes," said Kenneth L. Luskey, MD, VP Clinical Research at Intarcia. "ITCA 650 addresses some of the key limitations observed with other incretin mimetic therapies by eliminating the need for frequent self-injection, limiting the incidence and persistence of nausea and ensuring treatment compliance."

The phase 1b dose ranging study was conducted at multiple centers in the United States and evaluated a 28-day course of ITCA 650 treatment among patients with type 2 diabetes (10-12 patients/dose arm) on a stable treatment regimen of diet and exercise or treatment with metformin and/or thiazolidinediones. The study included 4 dose arms to which patients were randomized to receive 10 mcg/day, 20mcg/day, 40 mcg/day or 80 mcg/day exenatide for a 28 day treatment duration via a single insertion of ITCA 650. ITCA 650 therapy in this phase 1b trial was administered for the full course of treatment with a single insertion of the I
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... METTLER TOLEDO recently announced that D... “The Role of Process Analytical Technology ...uo; on December 1, 2009. , ...e of Process Analytical Technology (PAT) in Green ...er 1, Process Analytical Technology (PAT) case stu...
(Date:11/19/2009)...ELT, N.Y., Nov. 19 Dr. Mate Hidveg..., responds to a press release issued on November 1...mpany for making false and self-serving statements...,, Dr. Hidvegi stated from his office in Budape...earch on Avemar does not apply to AveULTRA, www....
(Date:11/19/2009)...ALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswir...on Resources find that the leading driver of antib...is broad-spectrum activity against gram-positive a...organisms that can cause nosocomial pneumonia, sur...imarily for agents that provide appropriate covera...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies For...o Coordinate Best Practices in Risk Reduction ,F...wide Gene Synthesis Capacity , ...ld’s leading gene synthesis companies today ...screening protocol to promote biosecurity in the g...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
... 30, 2009 Senomyx, Inc. (Nasdaq: SNMX ), a lead...ies to discover and develop novel flavor ingredien...ndustries, announced today the extension of the co...borative research and license agreement with Campb...er of high quality soup and simple meals. During ...
...bmits final study data to FDA for cervical cancer ...axoSmithKline (NYSE: GSK ) today provided the fo...S. Food and Drug Administration (FDA) for approval...ancer and cervical pre-cancer related to human pap...d final data from its Phase III pivotal efficacy s...
...nar , , MOUNTAIN VIEW, Calif., March 30 , , , ...t and the molecule,s, current a... diagnostics, and personalized t..., 2009, - TIME: 3 pm EDT, - LOCATI... Christi Bird, Senior Research Analyst, Healt...
Other Biology Technology:SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY 2SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY 3CERVARIX(R) U.S. Regulatory Update 2CERVARIX(R) U.S. Regulatory Update 3Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics 2
(Date:11/19/2009)...ain chemical with an unwieldy name: 4-hydroxybutyr...ed as a date-rape drug. , Now, a team of Ohio a...by which 4-HB is metabolized by the body. "This is...ibson, professor and chair of biological sciences ...of the research team. "It may provide new clues o...
(Date:11/19/2009)... many countries of the world. It is widely used fo...aterials. It also is considered an exemplar plant ...ution, and genome architecture. The authors of the...d the first description of the B73 maize genome to...netics and plant biology. The ten papers consider ...
(Date:11/19/2009)... 19 BIO-key Internationa...reless public safety and finger-based biometric id... Shareholder Meeting held today was adjourned with...t present. ,, (Logo: http://www.newscom.com/cg...ressive 99.3% of the 35 million votes cast voted i...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New Jersey Hospital Protects Patient Safety with Advanced Pharmacy Automation Solution 51167 1New Jersey Hospital Protects Patient Safety with Advanced Pharmacy Automation Solution 51167 2New Jersey Hospital Protects Patient Safety with Advanced Pharmacy Automation Solution 51167 32 reproductive factors are important predictors of death from ovarian cancer 9184 12 reproductive factors are important predictors of death from ovarian cancer 9184 22 reproductive factors are important predictors of death from ovarian cancer 9184 3Novel handheld device detects anthrax with outstanding accuracy and reliability 12945 1Novel handheld device detects anthrax with outstanding accuracy and reliability 12945 2Novel handheld device detects anthrax with outstanding accuracy and reliability 12945 3
...sts has identified a nesting population of leather...d,s largest. The research, published in the May is...-wide land and aerial surveys that estimated a pop...s using the nesting beaches. The study highlights ...sites and protected areas in Gabon. , Leatherback...
...is black, brittle and freeze-dried (just like the ... impressive feats. Designed by Northwestern Univer... water, easily separate hydrogen from other gases ...ective catalyst than the one currently used to pul... might be a mouthful, but it is also a widely used...
...edical School, along with collaborators from resea...es, have for the first time identified two genes t...enstruation. The work will be published in Nature...udy could have ramifications for normal human grow...is also associated with shorter stature and increa...
Other Biology News:Scientists identify world's largest leatherback turtle population 2One sponge-like material, three different applications 2One sponge-like material, three different applications 3Genes that influence start of menstruation identified for first time 2
...e MSQ™ Plus is a small and sensitive single...and IC. It features a newly designed self-cleaning... (API) source for outstanding sensitivity and nois...ing LC and IC methods, especially those including ...
...ne silencing experiments often call for critical, ...T NeoFX Transfection Agent refines siRNA transfect...RT NeoFXs lipid-based formulation can be used to e...bcultured without increased cytotoxicity. From st...
...ne silencing experiments often call for critical, ...T NeoFX Transfection Agent refines siRNA transfect...RT NeoFXs lipid-based formulation can be used to e...bcultured without increased cytotoxicity. From st...
jetSI conc. 10 mM from Polyplus Transfection
Biology Products: